Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells.

Pollock JK, Greene LM, Nathwani SM, Kinsella P, O'Boyle NM, Meegan MJ, Zisterer DM.

Invest New Drugs. 2018 Aug;36(4):523-535. doi: 10.1007/s10637-017-0543-z. Epub 2018 Feb 19.

PMID:
29460212
2.

Synthesis, Antiproliferative and Pro-Apoptotic Effects of Nitrostyrenes and Related Compounds in Burkitt's Lymphoma.

Byrne AJ, Bright SA, Fayne D, McKeown JP, McCabe T, Twamley B, Williams C, Meegan MJ.

Med Chem. 2018 Feb 6;14(2):181-199. doi: 10.2174/1573406413666171002123907.

PMID:
28969575
3.

Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.

Kelly PM, Keely NO, Bright SA, Yassin B, Ana G, Fayne D, Zisterer DM, Meegan MJ.

Molecules. 2017 Aug 31;22(9). pii: E1440. doi: 10.3390/molecules22091440.

4.

Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold.

Keely NO, Carr M, Yassin B, Ana G, Lloyd DG, Zisterer D, Meegan MJ.

Biomedicines. 2016 Jul 20;4(3). pii: E15. doi: 10.3390/biomedicines4030015.

5.

Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.

O'Boyle NM, Barrett I, Greene LM, Carr M, Fayne D, Twamley B, Knox AJS, Keely NO, Zisterer DM, Meegan MJ.

J Med Chem. 2018 Jan 25;61(2):514-534. doi: 10.1021/acs.jmedchem.6b01917. Epub 2017 May 1.

PMID:
28426931
6.

β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells.

Malebari AM, Greene LM, Nathwani SM, Fayne D, O'Boyle NM, Wang S, Twamley B, Zisterer DM, Meegan MJ.

Eur J Med Chem. 2017 Apr 21;130:261-285. doi: 10.1016/j.ejmech.2017.02.049. Epub 2017 Feb 24.

PMID:
28254699
7.

Piperlongumine (piplartine) and analogues: Antiproliferative microtubule-destabilising agents.

Meegan MJ, Nathwani S, Twamley B, Zisterer DM, O'Boyle NM.

Eur J Med Chem. 2017 Jan 5;125:453-463. doi: 10.1016/j.ejmech.2016.09.048. Epub 2016 Sep 16.

PMID:
27689728
8.

Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells.

Carr M, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ.

J Enzyme Inhib Med Chem. 2016;31(sup3):117-130. Epub 2016 Aug 1.

PMID:
27476825
9.

Synthesis, antiproliferative and pro-apoptotic activity of 2-phenylindoles.

Kelly PM, Bright SA, Fayne D, Pollock JK, Zisterer DM, Williams DC, Meegan MJ.

Bioorg Med Chem. 2016 Sep 15;24(18):4075-4099. doi: 10.1016/j.bmc.2016.06.050. Epub 2016 Jun 29.

PMID:
27407030
10.

Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents.

Greene TF, Wang S, Greene LM, Nathwani SM, Pollock JK, Malebari AM, McCabe T, Twamley B, O'Boyle NM, Zisterer DM, Meegan MJ.

J Med Chem. 2016 Jan 14;59(1):90-113. doi: 10.1021/acs.jmedchem.5b01086. Epub 2015 Dec 17.

PMID:
26680364
11.

Combretastatins: more than just vascular targeting agents?

Greene LM, Meegan MJ, Zisterer DM.

J Pharmacol Exp Ther. 2015 Nov;355(2):212-27. doi: 10.1124/jpet.115.226225. Epub 2015 Sep 9. Review.

12.

Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway.

Pollock JK, Verma NK, O'Boyle NM, Carr M, Meegan MJ, Zisterer DM.

Biochem Pharmacol. 2014 Dec 15;92(4):544-57. doi: 10.1016/j.bcp.2014.10.002. Epub 2014 Oct 22.

PMID:
25450669
13.

β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand.

O'Boyle NM, Pollock JK, Carr M, Knox AJ, Nathwani SM, Wang S, Caboni L, Zisterer DM, Meegan MJ.

J Med Chem. 2014 Nov 26;57(22):9370-82. doi: 10.1021/jm500670d. Epub 2014 Nov 17.

PMID:
25369367
14.

Synthesis and antiproliferative action of a novel series of maprotiline analogues.

McNamara YM, Bright SA, Byrne AJ, Cloonan SM, McCabe T, Williams DC, Meegan MJ.

Eur J Med Chem. 2014 Jan;71:333-53. doi: 10.1016/j.ejmech.2013.10.076. Epub 2013 Nov 9.

PMID:
24333581
15.

Structure-activity relationships in non-ligand binding pocket (non-LBP) diarylhydrazide antiandrogens.

Caboni L, Egan B, Kelly B, Blanco F, Fayne D, Meegan MJ, Lloyd DG.

J Chem Inf Model. 2013 Aug 26;53(8):2116-30. doi: 10.1021/ci400189m. Epub 2013 Jul 23.

PMID:
23834240
16.

Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer.

Greene LM, Wang S, O'Boyle NM, Bright SA, Reid JE, Kelly P, Meegan MJ, Zisterer DM.

Oncol Rep. 2013 Jun;29(6):2451-8. doi: 10.3892/or.2013.2379. Epub 2013 Apr 3.

PMID:
23564200
17.

Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting β-lactam combretastatins.

O'Boyle NM, Greene LM, Keely NO, Wang S, Cotter TS, Zisterer DM, Meegan MJ.

Eur J Med Chem. 2013 Apr;62:705-21. doi: 10.1016/j.ejmech.2013.01.016. Epub 2013 Jan 18.

PMID:
23454513
18.

Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro.

Nathwani SM, Hughes L, Greene LM, Carr M, O'Boyle NM, McDonnell S, Meegan MJ, Zisterer DM.

Oncol Rep. 2013 Feb;29(2):585-94. doi: 10.3892/or.2012.2181. Epub 2012 Dec 10.

PMID:
23232969
19.

Study of E/Z isomerization in a series of novel non-ligand binding pocket androgen receptor antagonists.

Blanco F, Egan B, Caboni L, Elguero J, O'Brien J, McCabe T, Fayne D, Meegan MJ, Lloyd DG.

J Chem Inf Model. 2012 Sep 24;52(9):2387-97. Epub 2012 Aug 17.

PMID:
22853713
20.

The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells.

Greene LM, O'Boyle NM, Nolan DP, Meegan MJ, Zisterer DM.

Biochem Pharmacol. 2012 Sep 1;84(5):612-24. doi: 10.1016/j.bcp.2012.06.005. Epub 2012 Jun 15.

PMID:
22705646
21.

"True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer.

Caboni L, Kinsella GK, Blanco F, Fayne D, Jagoe WN, Carr M, Williams DC, Meegan MJ, Lloyd DG.

J Med Chem. 2012 Feb 23;55(4):1635-44. doi: 10.1021/jm201438f. Epub 2012 Feb 10.

22.

Lead identification of β-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90.

O'Boyle NM, Knox AJ, Price TT, Williams DC, Zisterer DM, Lloyd DG, Meegan MJ.

Bioorg Med Chem. 2011 Oct 15;19(20):6055-68. doi: 10.1016/j.bmc.2011.08.048. Epub 2011 Aug 25.

PMID:
21920765
23.

Designed multiple ligands for cancer therapy.

O'Boyle NM, Meegan MJ.

Curr Med Chem. 2011;18(31):4722-37. Review.

PMID:
21919848
24.

Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe.

O'Boyle NM, Carr M, Greene LM, Keely NO, Knox AJ, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ.

Eur J Med Chem. 2011 Sep;46(9):4595-607. doi: 10.1016/j.ejmech.2011.07.039. Epub 2011 Jul 28.

PMID:
21840628
25.

The preservation of in vivo phosphorylated and activated uncoupling protein 3 (UCP3) in isolated skeletal muscle mitochondria following administration of 3,4-methylenedioxymethamphetamine (MDMA aka ecstasy) to rats/mice.

Kelly OM, McNamara YM, Manzke LH, Meegan MJ, Porter RK.

Mitochondrion. 2012 Jan;12(1):110-9. doi: 10.1016/j.mito.2011.03.011. Epub 2011 Mar 29.

PMID:
21453795
26.

Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones.

O'Boyle NM, Greene LM, Bergin O, Fichet JB, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ.

Bioorg Med Chem. 2011 Apr 1;19(7):2306-25. doi: 10.1016/j.bmc.2011.02.022. Epub 2011 Feb 17.

PMID:
21397510
27.

BubR1 is required for the mitotic block induced by combretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cells.

Greene LM, Carr M, Keeley NO, Lawler M, Meegan MJ, Zisterer DM.

Int J Mol Med. 2011 May;27(5):715-23. doi: 10.3892/ijmm.2011.633. Epub 2011 Mar 2.

PMID:
21369694
28.

Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents.

McNamara YM, Cloonan SM, Knox AJ, Keating JJ, Butler SG, Peters GH, Meegan MJ, Williams DC.

Bioorg Med Chem. 2011 Feb 1;19(3):1328-48. doi: 10.1016/j.bmc.2010.11.054. Epub 2010 Dec 7.

PMID:
21227702
29.

Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents.

O'Boyle NM, Carr M, Greene LM, Bergin O, Nathwani SM, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ.

J Med Chem. 2010 Dec 23;53(24):8569-84. doi: 10.1021/jm101115u. Epub 2010 Nov 16.

PMID:
21080725
30.

Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.

Carr M, Greene LM, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ.

Eur J Med Chem. 2010 Dec;45(12):5752-66. doi: 10.1016/j.ejmech.2010.09.033. Epub 2010 Sep 22.

PMID:
20933304
31.

The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.

Greene LM, Nathwani SM, Bright SA, Fayne D, Croke A, Gagliardi M, McElligott AM, O'Connor L, Carr M, Keely NO, O'Boyle NM, Carroll P, Sarkadi B, Conneally E, Lloyd DG, Lawler M, Meegan MJ, Zisterer DM.

J Pharmacol Exp Ther. 2010 Nov;335(2):302-13. doi: 10.1124/jpet.110.170415. Epub 2010 Aug 10.

32.

'tieredScreen' - Layered Virtual Screening Tool for the Identification of Novel Estrogen Receptor Alpha Modulators.

Yang Y, Carta G, Peters MB, Price T, O'Boyle N, Knox AJ, Fayne D, Williams DC, Meegan MJ, Lloyd DG.

Mol Inform. 2010 May 17;29(5):421-30. doi: 10.1002/minf.201000034. Epub 2010 May 17.

PMID:
27463197
33.

Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioamphetamines.

Cloonan SM, Keating JJ, Corrigan D, O'Brien JE, Kavanagh PV, Williams DC, Meegan MJ.

Bioorg Med Chem. 2010 Jun 1;18(11):4009-31. doi: 10.1016/j.bmc.2010.04.022. Epub 2010 Apr 13.

PMID:
20466553
34.

Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects.

Barrett I, Carr M, O'Boyle N, Greene LM, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ.

J Enzyme Inhib Med Chem. 2010 Apr;25(2):180-94. doi: 10.3109/14756360903169659.

PMID:
20222762
35.

Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells.

Nathwani SM, Butler S, Fayne D, McGovern NN, Sarkadi B, Meegan MJ, Lloyd DG, Campiani G, Lawler M, Williams DC, Zisterer DM.

Cancer Chemother Pharmacol. 2010 Aug;66(3):585-96. doi: 10.1007/s00280-009-1200-9. Epub 2009 Dec 18.

PMID:
20020128
36.

Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents.

Cloonan SM, Keating JJ, Butler SG, Knox AJ, Jørgensen AM, Peters GH, Rai D, Corrigan D, Lloyd DG, Williams DC, Meegan MJ.

Eur J Med Chem. 2009 Dec;44(12):4862-88. doi: 10.1016/j.ejmech.2009.07.027. Epub 2009 Aug 6.

PMID:
19717215
37.

Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines.

Nathwani SM, Butler S, Meegan MJ, Campiani G, Lawler M, Williams DC, Zisterer DM.

Cancer Chemother Pharmacol. 2010 Jan;65(2):289-300. doi: 10.1007/s00280-009-1033-6.

PMID:
19479253
38.

Targeting tumors using estrogen receptor ligand conjugates.

Keely NO, Meegan MJ.

Curr Cancer Drug Targets. 2009 May;9(3):370-80. Review.

PMID:
19442056
39.

Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.

Knox AJ, Price T, Pawlak M, Golfis G, Flood CT, Fayne D, Williams DC, Meegan MJ, Lloyd DG.

J Med Chem. 2009 Apr 23;52(8):2177-80. doi: 10.1021/jm801569z.

PMID:
19331414
40.

The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.

Bright SA, Greene LM, Greene TF, Campiani G, Butini S, Brindisi M, Lawler M, Meegan MJ, Williams DC, Zisterer DM.

Biochem Pharmacol. 2009 Feb 1;77(3):310-21. doi: 10.1016/j.bcp.2008.10.008. Epub 2008 Oct 30.

PMID:
19014913
41.

Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.

Barrett I, Meegan MJ, Hughes RB, Carr M, Knox AJ, Artemenko N, Golfis G, Zisterer DM, Lloyd DG.

Bioorg Med Chem. 2008 Nov 1;16(21):9554-73. doi: 10.1016/j.bmc.2008.09.035. Epub 2008 Sep 16.

PMID:
18835176
42.

Beta-lactam type molecular scaffolds for antiproliferative activity: synthesis and cytotoxic effects in breast cancer cells.

Meegan MJ, Carr M, Knox AJ, Zisterer DM, Lloyd DG.

J Enzyme Inhib Med Chem. 2008 Oct;23(5):668-85. doi: 10.1080/14756360802469127 .

PMID:
18821256
43.

Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter.

Butler SG, Meegan MJ.

Curr Med Chem. 2008;15(17):1737-61. Review.

PMID:
18673223
44.

Virtual screening of the estrogen receptor.

Knox AJ, Yang Y, Lloyd DG, Meegan MJ.

Expert Opin Drug Discov. 2008 Aug;3(8):853-66. doi: 10.1517/17460441.3.8.853.

PMID:
23484963
45.

Benzothiepin-derived molecular scaffolds for estrogen receptor modulators: synthesis and antagonistic effects in breast cancer cells.

Meegan MJ, Barrett I, Zimmermann J, Knox AJ, Zisterer DM, Lloyd DG.

J Enzyme Inhib Med Chem. 2007 Oct;22(5):655-66.

PMID:
18035834
46.

Target specific virtual screening: optimization of an estrogen receptor screening platform.

Knox AJ, Meegan MJ, Sobolev V, Frost D, Zisterer DM, Williams DC, Lloyd DG.

J Med Chem. 2007 Nov 1;50(22):5301-10. Epub 2007 Oct 5.

PMID:
17918820
47.
48.
49.
50.

Oncology exploration: charting cancer medicinal chemistry space.

Lloyd DG, Golfis G, Knox AJ, Fayne D, Meegan MJ, Oprea TI.

Drug Discov Today. 2006 Feb;11(3-4):149-59. Review.

PMID:
16533713

Supplemental Content

Loading ...
Support Center